Treatment of Metastatic or Recurrent Lip and Oral Cavity Cancer
When lip or oral cavity cancer recurs locally or presents with distant metastasis, the therapeutic focus shifts to systemic management. This page summarises the clinical scenario and the general first-line treatment direction for this population.
Clinical Scenario
Metastatic or recurrent disease affecting the lip, anterior tongue, buccal mucosa, floor of the mouth, retromolar trigone, upper gingiva, or hard palate. In this setting, treatment selection is guided by the specific location and size of the recurrent lesion as well as any therapies the patient has previously received.
First-Line Treatment Approach Partial summary
First-line management for metastatic or recurrent disease in this population centres on immunotherapy targeting the PD-1 pathway. Whether a combination regimen or monotherapy is most appropriate depends on tumour biomarker profile — the complete algorithm, including all options and eligibility criteria, is available in the full structured protocol.
Full regimen details, sequencing, and eligibility criteria are not shown here.
References
- For lesions of the lip, anterior tongue, buccal mucosa, floor of the mouth, retromolar trigone, upper gingiva, and hard palate, treatment is dictated by the location and size of the recurrent lesion as well as prior treatment.
- Pembrolizumab plus a platinum and 5-FU is an appropriate first-line treatment for patients with metastatic or recurrent head and neck SCC.
- Pembrolizumab monotherapy is an appropriate first-line treatment for patients with PD-L1–positive metastatic or recurrent head and neck SCC.
View source ↗